Kidney transplant patients face higher skin cancer risk

September 28, 2005

People who receive a kidney transplant are nearly four times more likely than the general population to develop melanoma, a rare but deadly form of skin cancer, according to a study led by Christopher Hollenbeak, Ph.D., associate professor, Departments of Surgery and Health Evaluation Sciences, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center.

The study, to be published in CANCER, a peer-reviewed journal of the American Cancer Society (Nov.1, 2005 issue), indicates increased risk for patients who undergo kidney transplantation and who receive long-term immuno-suppression. Furthermore, risk was highest overall in men -increasing with age- but significantly lower in women and African-Americans.

"The take-home message is that kidney transplant patients-especially men-should have a regular, complete skin examination as part of their routine health care," says Hollenbeak. "In addition, kidney transplant recipients should be educated about melanoma and instructed on the importance of routine self-examination."

In the largest study to date, Hollenbeak and his colleagues compared melanoma incidence rates from a registry of renal transplant patients (89,786 patients) to melanoma incidence rates from general population data.

Of the various types of skin cancer, melanoma is one of the deadliest, with a mortality rate up to 6 percent in some regions of the world. The classic risk factors for melanoma are ultraviolet radiation, commonly caused by sunburns, a suppressed immune system, and family history of abnormal moles. Studies demonstrate that the immune system plays a critical role in monitoring the body for-and destroying-early cancerous cells, including melanoma.

Prior studies have shown that patients taking immunosuppressants after organ transplantation to be at higher risk for all cancers, but disagree that there is a link to higher risk of skin cancer. The baseline low incidence of melanoma in the general population may contribute to conflicting data. Low incidence of disease means that more people need to be studied to discern a true link between immunosupressants and a greater risk for melanoma.

They found that renal transplant recipients are 3.6 times more likely to develop melanoma than the general population. Though some melanomas will develop immediately after transplant, risk continues to increase approximately 5 percent per year from date of transplant. Men who have had a kidney transplant are at greatest risk for melanoma, and risk of melanoma increases rapidly with age. In contrast, while female kidney transplant recipients are also at increased risk, their risk is significantly lower than men and does not increase with age.

"Kidney transplant patients, who are receiving long-term immunosuppression," conclude Hollenbeak and his colleagues, "have a 3.6-fold increase in the incidence of melanoma when compared to the general population," and should receive regular complete skin examinations.
-end-
Article: "Increased Incidence of Melanoma in Renal Transplantation Recipients," Christopher S. Hollenbeak, Ph.D., Departments of Surgery, Penn State College of Medicine; Michael M. Todd, M.D., Skin Cancer Center of Northern Virginia; Elizabeth M. Billingsley, M.D., Department of Dermatology, Penn State Milton S. Hershey Medical Center; Gregory Harper, M.D., Ph.D., Penn State Cancer Institute, Lehigh Valley Hospital; Anne-Marie Dyer, M.S. Department of Health Evaluation Sciences, Penn State College of Medicine; Eugene J. Lengerich, V.M.D., M.S. Department of Health Evaluation Sciences, Penn State Cancer Institute, Penn State College of Medicine: CANCER; Published Online: Sept. 26, 2005 (DOI: 10.1002/cncr.21404); Print issue: Nov. 1, 2005.

Penn State

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.